Cargando…

Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3

BACKGROUND: VIKING-3 aimed to examine efficacy and safety of dolutegravir (DTG) 50 mg twice daily in patients with resistance to multiple ARV classes, including integrase inhibitors (INI). METHODS: RAL and/or EVG-resistant (current or historical) adult subjects with screening plasma HIV-1 RNA ≥500 c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nichols, G, Mills, A, Grossberg, R, Lazzarin, A, Maggiolo, F, Molina, J, Pialoux, G, Wright, D, Ait-Khaled, M, Huang, J, Vavro, C, Wynne, B, Yeo, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2012
Materias:	Oral Abstract – O232
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512486/ http://dx.doi.org/10.7448/IAS.15.6.18112

Ejemplares similares

USIR : unité pivot des détresses respiratoires : une année de pandémie à SARS-CoV-2
por: Foulquier, S., et al.
Publicado: (2022)

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
por: Eron, J, et al.
Publicado: (2010)

Sport practice and plantar pressure in children aged 10–18 years: evaluation using Namrol® Podoprint®
por: Lopes, C., et al.
Publicado: (2021)

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
por: Castagna, Antonella, et al.
Publicado: (2014)

HIV epidemic in Russia and neighbouring countries
por: Pokrovskiy, Vadim
Publicado: (2014)

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
por: Eron, Joseph J., et al.
Publicado: (2013)

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014)

765 When All Hell Breaks Loose: The Need for Specialized Burn Provider Expertise During Crisis
por: Goff, Anna, et al.
Publicado: (2023)

766 Evaluating the Ethics of Comfort Care in Self-Immolation Burns
por: Pham, Theophilus, et al.
Publicado: (2023)

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study
por: Vavro, Cindy, et al.
Publicado: (2022)

Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens
por: Batterham, Rachel L, et al.
Publicado: (2023)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
por: Molina, Jean-Michel, et al.
Publicado: (2014)

The Viking world /
por: Graham-Campbell, James
Publicado: (1980)

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
por: Gil, Horacio, et al.
Publicado: (2022)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

Covid-19 abruptly halted the 2020 afl season. what was the impact on athlete performance?
por: Heffernan, O., et al.
Publicado: (2022)

7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
por: Ziegler, Robert E., et al.
Publicado: (2018)

Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor
por: Nilavar, Namrata M., et al.
Publicado: (2020)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
por: Mandikiyana Chirimuta, Linda A., et al.
Publicado: (2022)

Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study
por: van Wyk, Jean, et al.
Publicado: (2021)

Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
por: Thierry, Eloïse, et al.
Publicado: (2017)

Magical medicine in Viking Scandinavia.
por: Robertson, D
Publicado: (1976)

Théorie de la discontinuité : un rôle de l’infection à SARS-CoV-2 dans le développement de l’auto-immunité ?
por: Scherlinger, M., et al.
Publicado: (2022)

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance
por: Demarest, James, et al.
Publicado: (2018)

Potential drug–drug interactions in HIV-perinatally infected adolescents on antiretroviral therapy in Buenos Aires, Argentina
por: Cordova, Ezequiel, et al.
Publicado: (2014)

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)

Dupuytren's Disease: the Vikings Disease in Koreans
por: Gong, Hyun Sik
Publicado: (2018)

Success of sky-polarimetric Viking navigation: revealing the chance Viking sailors could reach Greenland from Norway
por: Száz, Dénes, et al.
Publicado: (2018)

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1
por: Evitt, Lee A., et al.
Publicado: (2023)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
por: Smith, Robert A, et al.
Publicado: (2015)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

Brachial plexus neuropathies during the COVID-19 pandemic: A retrospective case series of 15 patients in critical care
por: O'Sullivan, J., et al.
Publicado: (2022)

A retrospective review of the use of text message communication for a musculoskeletal service during COVID-19
por: Waters, L., et al.
Publicado: (2022)

COVID-19: Physiotherapy students experience during practice placement in the United Kingdom
por: Haghighi, T., et al.
Publicado: (2022)

A mixed-methods survey to explore issues with virtual consultations for musculoskeletal care during the COVID-19 pandemic
por: Gilbert, A., et al.
Publicado: (2022)

Evaluation of patient reported outcomes following pain management programmes delivered via video conferencing during the Covid-19 pandemic
por: Heelas, L., et al.
Publicado: (2022)

Facteurs de risque de réponse insuffisante à la vaccination contre la COVID-19 chez les patients traités par rituximab
por: Avouac, J., et al.
Publicado: (2021)

Impact des JAK inhibiteurs sur la réponse vaccinale anti-SARS-CoV-2 : données du registre MAJIK-SFR
por: Seror, R., et al.
Publicado: (2021)

Facteurs associés au refus de la vaccination contre le SARS-Cov-2 chez les patients atteints de rhumatismes inflammatoires chroniques (étude VACCI-RIC)
por: Lohse, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oas1vocbsffkfhe8h2iqkfksja